Topotecan in second-line therapy of SCLC: Impact on survival?

Onkologie

Volumn 23, Issue SUPPL. 3, 2000, Pages 9-12

  Huber, Rudolf M ^a,j   Gatzemeier, U ^b   Gosse, H ^c   Von Pawel, J ^d   Hruska, D ^e   Mezger, J ^f   Saal, J G ^g   Kleinschmidt, R ^h   Steppert, C ⁱ   Steppling, H ^k  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c Städtische Klinik Leipzig   (Germany)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^e Schillerhöhe Hospital   (Germany)

^f Frauenkl St Vincentius K   (Germany)

^g St Franziskus Hospital   (Germany)

^h UNIVERSITY OF BONN   (Germany)

ⁱ Fachklinik Kutzenberg   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0034038493     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055042     Document Type: Article

References (12)

1. American Cancer Society: Cancer Facts & Figures. Atlanta, GA. American Cancer Society, 1997.
2. Minna JD: Neoplasms of the lung; in Isselbacher KJ, Braunwald E, Wilson, JD (eds): Harrison's Principles of Internal Medicine, New York, Mc Graw-Hill, 1994, pp 1221-1229.
3. Ihde DC, Pass HI, Glatstein EJ: Small-cell lung cancer: in DeVita VT, Hellmann S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott-Raven, 1993, p 749.
4. Sculier JP, Klastersky J, Libert P: A phase II study evaluating CAVi (cyclophosphamide, adriamycine, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 1990;6:110-118.
5. Shepard FA, Evans WK, MacCormick R, Feld R, Yau JC: Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer. Cancer Treat Rep 1987;71:941-944.
6. Albain KS, Crowley JJ, Hutchins L, Gandara D, O'Bryan RM, Von Hoff DD, Griffin B, Livingston RB: Predictors of survival following relapse or progression of small small cell lung cancer. Cancer 1993;72:1184-1191.
7. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
8. Eckardt J, Gralla R, Palmer MC: Topotecan (T) as second-line therapy in patients (pts) in small cell lung cancer (SCLC): A phase II study. Ann Oncol 1996;7:107(abstr 513).
9. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J Clin Oncol 1999;17:658-667.
10. Lane SR, Fitts DA, Ross G, Fields SZ: Relationship between tumor response and survival in small-cell lung patients treated with intravenous topotecan as second-line therapy. Proc ASCO 1998;17:1896.
11. Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996;14:2785-2790.
12. Armstrong D, O'Reilly S: Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist 1998;3:4-10.